Kelly Chen, NP
Nurse Practitioner · Stanford, CANPI 1942765391
Payments from drug & device makers
Across 43 payments — averaging $395.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- Medtronic$1K
- Novartis$1K
- Amgen$145
- Idorsia Pharmaceuticals US Inc$122
- Aurinia Pharma U.S., Inc.$113
- plus $100 from 1 others
Across 1 payment — averaging $7228.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7K
What the payments were for
- Consulting fees$11,93370%
- Speaking & faculty fees$1,0966%
- Travel & lodging$2,64216%
- Food & beverage$1,3388%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 21 | $14,244 |
| Medtronic | 15 | $1,169 |
| Novartis | 2 | $1,117 |
| Amgen | 1 | $145 |
| Idorsia Pharmaceuticals US Inc | 2 | $122 |
| Aurinia Pharma U.S., Inc. | 1 | $113 |
| Nxstage Medical, Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$181
- KRYSTEXXA$145
- LUPKYNIS$113
How this compares
$17,009 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 43 | $40,553 |
| FarxigaDapagliflozin Propanediol | 43 | $39,423 |
| Eplerenone | 63 | $11,828 |
| Losartan Potassium | 82 | $674 |
| Spironolactone | 40 | $669 |
| Chlorthalidone | 42 | $534 |
| Amlodipine Besylate | 74 | $510 |
| Carvedilol | 46 | $414 |
| Furosemide | 31 | $347 |
| Torsemide | 17 | $297 |
| Lisinopril | 24 | $290 |
| Calcitriol | 19 | $272 |
| Doxazosin Mesylate | 16 | $233 |
| Hydralazine Hcl | 14 | $77 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Stanford
- Rhonda HewittStanford$917K
- Hamta ZareStanford$428K
- Theresa Mallick-SearleStanford$193K
- Martina SpeightStanford$170K
- Helen ShihStanford$104K
- Connie WolfordStanford$69K
- Michelle GapayStanford$37K
- Elaine JangStanford$32K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.